Clinical trial NCT01865747: A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Official title: A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Renal Cell Carcinoma
Keywords: renal cell cancer
kidney
vascular endothelial growth factor receptor 2 (VEGFR2)
tyrosine kinase inhibitor
hepatocyte growth factor receptor protein (MET)
von Hippel-Lindau gene
Lead sponsor: Exelixis
Sponsor class: INDUSTRY
First posted: 2013-05-31
Enrollment: 658
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.


Eligibility criteria: Select Inclusion Criteria:

1. Documented histological or cytological diagnosis of renal cell cancer with a clear-cell component.
2. Measurable disease as determined by the investigator.
3. Must have received at least one VEGFR-targeting TKI (eg, sorafenib, sunitinib, axitinib, pazopanib or tivozanib).
4. Recovery from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
5. Adequate organ and marrow function.
6. Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.
7. Female subjects of childbearing potential must not be pregnant at screening.

Select Exclusion Criteria:

1. Prior treatment with everolimus, or any other specific or selective TORC1/PI3K/AKT inhibitor (eg, temsirolimus), or cabozantinib.
2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before randomization.
3. Receipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before randomization.
4. Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Systemic treatment with radionuclides within 6 weeks before randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.
6. Concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitors.
7. Chronic treatment with corticosteroids or other immunosuppressive agents.
8. Serious illness other than cancer.
9. Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before randomization and from minor surgery at least 10 days before randomization.
10. Pregnant or lactating females.
11. Diagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low grade tumors.

Primary outcomes:
measure: Progression-free Survival (PFS)
timeFrame: PFS is measured from the date of randomization until the date of first documented disease progression or date of death from any cause as determined by the Independent Radiology Committee (IRC) per RECIST 1.1, assessed for up to 17 months.
Secondary outcomes:
measure: Overall Survival (OS)
timeFrame: OS was measured from the time of randomization until 320 deaths, approximately 28 months
measure: Objective Response Rate (ORR)
timeFrame: ORR was assessed at 8 weeks post-randomization, every 8 weeks for 12 months, and every 12 weeks until date of disease progression or death, up to May 2015 (approximately 21 months)
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Anchorage
country: United States
state: Alaska
city: Gilbert
country: United States
state: Arizona
city: Scottsdale
country: United States
state: Arizona
city: Tucson
country: United States
state: Arizona
city: Duarte
country: United States
state: California
city: La Jolla
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: Vallejo
country: United States
state: California
city: Aurora
country: United States
state: Colorado
city: Denver
country: United States
state: Colorado
city: New Haven
country: United States
state: Connecticut
city: Washington
country: United States
state: District of Columbia
city: Boca Raton
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Orlando
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: Chicago
country: United States
state: Illinois
city: Chicago
country: United States
state: Illinois
city: Chicago
country: United States
state: Illinois
city: Iowa City
country: United States
state: Iowa
city: Westwood
country: United States
state: Kansas
city: Baltimore
country: United States
state: Maryland
city: Baltimore
country: United States
state: Maryland
city: Boston
country: United States
state: Massachusetts
city: Ann Arbor
country: United States
state: Michigan
city: Detroit
country: United States
state: Michigan
city: Detroit
country: United States
state: Michigan
city: Rochester
country: United States
state: Minnesota
city: Saint Louis
country: United States
state: Missouri
city: Las Vegas
country: United States
state: Nevada
city: Albany
country: United States
state: New York
city: New York
country: United States
state: New York
city: Durham
country: United States
state: North Carolina
city: Cleveland
country: United States
state: Ohio
city: Cleveland
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Portland
country: United States
state: Oregon
city: Portland
country: United States
state: Oregon
city: Philadelphia
country: United States
state: Pennsylvania
city: Pittsburgh
country: United States
state: Pennsylvania
city: Charleston
country: United States
state: South Carolina
city: Knoxville
country: United States
state: Tennessee
city: Memphis
country: United States
state: Tennessee
city: Nashville
country: United States
state: Tennessee
city: Nashville
country: United States
state: Tennessee
city: Austin
country: United States
state: Texas
city: Bedford
country: United States
state: Texas
city: Dallas
country: United States
state: Texas
city: Fort Worth
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Salt Lake City
country: United States
state: Utah
city: Seattle
country: United States
state: Washington
city: Vancouver
country: United States
state: Washington
city: Yakima
country: United States
state: Washington
city: La Plata
country: Argentina
state: Buenos Aires
city: Mar Del Plata
country: Argentina
city: Concord
country: Australia
state: New South Wales
city: Darlinghurst
country: Australia
state: New South Wales
city: Kogarah
country: Australia
state: New South Wales
city: Port Macquarie
country: Australia
state: New South Wales
city: Randwick
country: Australia
state: New South Wales
city: Wahroonga
country: Australia
state: New South Wales
city: Westmead
country: Australia
state: New South Wales
city: Milton
country: Australia
state: Queensland
city: Wooloongabba
country: Australia
state: Queensland
city: Adelaide
country: Australia
state: South Australia
city: Hobart
country: Australia
state: Tasmania
city: Bentleight East
country: Australia
state: Victoria
city: Box Hill
country: Australia
state: Victoria
city: Wodonga
country: Australia
state: Victoria
city: Linz
country: Austria
state: Oberösterreich
city: Wien
country: Austria
city: Wien
country: Austria
city: Bonheiden
country: Belgium
state: Antwerpen
city: Brasschaat
country: Belgium
state: Antwerpen
city: Bruxelles
country: Belgium
state: Brussels
city: Leuven
country: Belgium
state: Vlaams Brabant
city: Roeselare
country: Belgium
state: West-Vlaanderen
city: Antwerpen
country: Belgium
city: Liege
country: Belgium
city: Calgary
country: Canada
state: Alberta
city: Edmonton
country: Canada
state: Alberta
city: Vancouver
country: Canada
state: British Columbia
city: Winnepeg
country: Canada
state: Manitoba
city: Halifax
country: Canada
state: Nova Scotia
city: Hamilton
country: Canada
state: Ontario
city: Kingston
country: Canada
state: Ontario
city: London
country: Canada
state: Ontario
city: Oshawa
country: Canada
state: Ontario
city: Ottawa
country: Canada
state: Ontario
city: Toronto
country: Canada
state: Ontario
city: Toronto
country: Canada
state: Ontario
city: Montreal
country: Canada
state: Quebec
city: Saskatoon
country: Canada
state: Saskatchewan
city: Santiago
country: Chile
city: Olomouc
country: Czechia
state: Olomoucký Kraj
city: Brno
country: Czechia
city: Prague
country: Czechia
city: Herlev
country: Denmark
state: Hovedstaden
city: Aarhus
country: Denmark
state: Midtjylland
city: Odense
country: Denmark
state: Syddanmark
city: Turku
country: Finland
state: Länsi-Suomen Lääni
city: Helsinki
country: Finland
city: Caen
country: France
state: Calvados
city: Besancon
country: France
state: Doubs
city: Bordeaux
country: France
state: Gironde
city: Toulouse
country: France
state: Haute-Garonne
city: Rennes
country: France
state: Ille-et-Vilaine
city: Nantes
country: France
state: Loire-Atlantique
city: Lyon
country: France
state: Rhône
city: Le Mans
country: France
state: Sarthe
city: Villejuif
country: France
state: Val-de-Marne
city: Marseille
country: France
city: Paris
country: France
city: Freiburg
country: Germany
state: Baden Wuttemberg
city: Tubingen
country: Germany
state: Baden-Württemberg
city: Ulm
country: Germany
state: Baden-Württemberg
city: Erlangen
country: Germany
state: Bayern
city: Aachen
country: Germany
state: Nordrhein-Westfalen
city: Essen
country: Germany
state: Nordrhein-Westfalen
city: Mainz
country: Germany
state: Rheinland-Pfalz
city: Jena
country: Germany
state: Thuringen
city: Erfurt
country: Germany
state: Thüringen
city: Berlin
country: Germany
city: Dresden
country: Germany
city: Frankfurt am Main
country: Germany
city: Guetersloh
country: Germany
city: Hamburg
country: Germany
city: Hannover
country: Germany
city: Heidelberg
country: Germany
city: Munchen
country: Germany
city: Munich
country: Germany
city: Budapest
country: Hungary
city: Szolnok
country: Hungary
city: Dublin
country: Ireland
city: Dublin
country: Ireland
city: Meldola
country: Italy
state: Emilia-Romagna
city: Modena
country: Italy
state: Emilia-Romagna
city: Ravenna
country: Italy
state: Emilia-Romagna
city: Rome
country: Italy
state: Lazio
city: Rome
country: Italy
state: Lazio
city: Genova
country: Italy
state: Liguria
city: Cremona
country: Italy
state: Lombardia
city: Bari
country: Italy
state: Puglia
city: Arezzo
country: Italy
state: Toscana
city: Terni
country: Italy
state: Umbria
city: Seoul
country: Korea, Republic of
city: Seoul
country: Korea, Republic of
city: Seoul
country: Korea, Republic of
city: Maastricht
country: Netherlands
state: Limburg
city: Amsterdam
country: Netherlands
state: Noord-Holland
city: Leiden
country: Netherlands
state: Zuid-Holland
city: Rotterdam
country: Netherlands
state: Zuid-Holland
city: Bialystok
country: Poland
state: Podlaskie
city: Gdansk
country: Poland
state: Pomorskie
city: Poznan
country: Poland
state: Wielkopolskie
city: Warsaw
country: Poland
city: Lisbon
country: Portugal
city: Lisbon
country: Portugal
city: Porto
country: Portugal
city: Moscow
country: Russian Federation
city: Omsk
country: Russian Federation
city: St. Petersburg
country: Russian Federation
city: Yaroslavl
country: Russian Federation
city: Presov
country: Slovakia
city: Zilina
country: Slovakia
city: Oviedo
country: Spain
state: Asturias
city: Barcelona
country: Spain
state: Cataluna
city: Badalona
country: Spain
state: Cataluña
city: L'Hospitalet de Llobregat
country: Spain
state: Cataluña
city: Pamplona
country: Spain
state: Navarra
city: Barcelona
country: Spain
city: Madrid
country: Spain
city: Madrid
country: Spain
city: Madrid
country: Spain
city: Málaga
country: Spain
city: Santiago de Compostela
country: Spain
city: Seville
country: Spain
city: Valencia
country: Spain
city: Lund
country: Sweden
state: Skane Lan
city: Stockholm
country: Sweden
state: Sodermanlands Lan
city: Umea
country: Sweden
city: Taichung
country: Taiwan
city: Taipei
country: Taiwan
city: Ankara
country: Turkey
city: Gaziantep
country: Turkey
city: Istanbul
country: Turkey
city: Izmir
country: Turkey
city: Birmingham
country: United Kingdom
state: England
city: Derby
country: United Kingdom
state: England
city: Guildford
country: United Kingdom
state: England
city: London
country: United Kingdom
state: England
city: London
country: United Kingdom
state: England
city: London
country: United Kingdom
state: England
city: Manchester
country: United Kingdom
state: England
city: Northwood
country: United Kingdom
state: England
city: Wirral
country: United Kingdom
state: England
city: Aberdeen
country: United Kingdom
state: Scotland
city: Edinburgh
country: United Kingdom
state: Scotland
city: Glasgow
country: United Kingdom
state: Scotland
Study officials:
References:
citation: Denize T, Farah S, Cimadamore A, Flaifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, Xie W, Choueiri TK, Signoretti S. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2022 Feb 15;28(4):748-755. doi: 10.1158/1078-0432.CCR-21-3088.
citation: Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Aug 7;21(1):904. doi: 10.1186/s12885-021-08630-w.
citation: Donskov F, Motzer RJ, Voog E, Hovey E, Grullich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2020 Feb;126:1-10. doi: 10.1016/j.ejca.2019.10.032. Epub 2019 Dec 27.
citation: Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1.
citation: Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol. 2018 Mar 10;36(8):757-764. doi: 10.1200/JCO.2017.75.2170. Epub 2018 Jan 29.
citation: Escudier B, Powles T, Motzer RJ, Olencki T, Aren Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Lougheed JC, Bracarda S, Choueiri TK. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. J Clin Oncol. 2018 Mar 10;36(8):765-772. doi: 10.1200/JCO.2017.74.7352. Epub 2018 Jan 8.
citation: Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.
citation: Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.